MARKET

CRVS

CRVS

Corvus Pharmaceu
NASDAQ
4.960
-0.070
-1.39%
After Hours: 4.990 +0.03 +0.60% 18:27 02/11 EST
OPEN
5.01
PREV CLOSE
5.03
HIGH
5.25
LOW
4.910
VOLUME
747.77K
TURNOVER
--
52 WEEK HIGH
10.00
52 WEEK LOW
1.300
MARKET CAP
318.72M
P/E (TTM)
-5.3552
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CRVS last week (0203-0207)?
Weekly Report · 1d ago
Weekly Report: what happened at CRVS last week (0127-0131)?
Weekly Report · 02/03 11:02
Weekly Report: what happened at CRVS last week (0120-0124)?
Weekly Report · 01/27 11:04
Weekly Report: what happened at CRVS last week (0113-0117)?
Weekly Report · 01/20 10:57
Corvus Pharmaceuticals Price Target Maintained With a $11.00/Share by HC Wainwright & Co.
Dow Jones · 01/14 11:35
Buy Recommendation for Corvus Pharmaceuticals Driven by Soquelitinib’s Promising Trial Results and Strong Financial Position
TipRanks · 01/14 11:29
HC Wainwright & Co. Reiterates Buy on Corvus Pharma, Maintains $11 Price Target
Benzinga · 01/14 11:24
Corvus Pharmaceuticals Reports Promising Interim Data on Soquelitinib
TipRanks · 01/13 13:30
More
About CRVS
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, a selective, covalent inhibitor of ITK (interleukin 2 inducible T cell kinase) and is in a multi-center Phase 1/1b clinical trial in patients with various recurrent, malignant T cell lymphomas. Soquelitinib is designed to inhibit the proliferation of certain malignant T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.

Webull offers Corvus Pharmaceuticals Inc stock information, including NASDAQ: CRVS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRVS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRVS stock methods without spending real money on the virtual paper trading platform.